In the last decade, it has become increasingly clear that a gut full of friendly microbes (the microbiome) is vital for our good health. It has also become clear that a healthy microbiome is one with a diverse population of microbes (bacteria, viruses, fungi). What we haven’t known is why a diverse array of friendly bugs is important for keeping the harmful microbes (pathogens) at bay. But now we think we have found the answer.
Our latest study, published in Science, shows that the main reason a diverse microbiome is helpful for resisting pathogens is that the friendly microbes collectively consume the nutrients needed for a pathogen to grow in the gut.
In other words, a diverse microbiome blocks pathogen growth by using its nutrients – a phenomenon we call “nutrient blocking”. Understanding how nutrient blocking works is powerful because it allows us to predict which gut communities will be protective against a given pathogen.
Our research team started by conducting a large screen of 100 common strains of human gut bacteria. We tested the individual ability of these strains to restrict the growth of two bacterial pathogens, Klebsiella pneumoniae and Salmonella enterica serovar Typhimurium. These two species are a problem because many strains are becoming resistant to antibiotics.
Alone, the gut strains could not prevent pathogen growth. However, this was different when several of these species were pooled into larger communities. Higher diversity communities tended to offer more protection against invading pathogens, both in test-tube experiments and when tested in mice.
However, not all higher diversity communities tested restricted pathogen growth. Crucially, certain species must be present for a community to be protective.
We then went on to investigate the reason why. We compared the nutrients that could be consumed by each of the individual species with the nutrients consumed by the pathogens. We realised that certain gut species had a higher nutrient use overlap with the pathogens than other species.
Still, individually, the nutrient use overlap of even these key species with the pathogens was not high enough to block pathogen growth. But when we considered which nutrients the community as a whole can use, we found that the communities with the highest degree of overlap with the pathogens provided the most protection.
Suggesting treatments
This finding is important as it provides a route for the design of beneficial, probiotic communities that aim to boost the microbiome’s ability to resist colonisation by disease-causing pathogens.
We tested this idea by taking a set of 50 human gut species and predicting which combinations of species would be protective against a new pathogen: a drug-resistant Escherichia coli.

Some strains of E coli bacteria (seen here) cause us harm. CDC/Janice Haney Carr
We selected the communities that were predicted to be poor at blocking the growth of this pathogenic E coli isolate, and communities that were predicted to be good, and tested them against the new pathogen. In all cases, the nutrient blocking principle was able to successfully predict the ability of the community to block the growth of the pathogen.
Antibiotic treatment failure is becoming more common due to the spread of resistant pathogens. Alternative solutions that harness the body’s natural ability to resist disease, such as by tinkering with the microbiome’s composition, are becoming more attractive.
The gut microbiome is integral to our health, but it is very complex and therefore hard to understand. Our study provides a template for how one might rationally design probiotic communities to engineer microbiomes for better health.


U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
FDA Pilot Program Eases Rules for Nicotine Pouch Makers
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 



